Form 4/A for FATE FATE THERAPEUTICS INC
Accepted 2022-02-04 00:00:00 ET · period of report 2022-01-20 · accession 0000899243-22-004871 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DA | 2022-02-04 | 2022-01-20 | FATE | Wolchko J Scott | Pres, CEO, Dir | M - OptEx | $2.70 | +30.0K | 461.5K | +7% | +$81.0K |
| DMA | 2022-02-04 | 2022-01-20+ | FATE | Wolchko J Scott | Pres, CEO, Dir | M - OptEx | $0.00 | -40.0K | 86.2K | -32% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-20 | M | A | 30,000 | $2.70 | 461,546 | D | — | — | (F2) Corrected option price. |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-01-21 | M | D | 10,000 | $0.00 | 76,246 | D | $2.70 · — to 2026-01-11 | 10,000 Common Stock | (F4) Corrected ending balance of this option which includes 36,800 shares that are vested and outstanding pursuant to a second option grant issued on January 12, 2016. (F3) This stock option is fully vested. |
| 3 | Derivative | Stock Option (Right to Buy) | 2022-01-20 | M | D | 30,000 | $0.00 | 86,246 | D | $2.70 · — to 2026-01-11 | 30,000 Common Stock | (F4) Corrected ending balance of this option which includes 36,800 shares that are vested and outstanding pursuant to a second option grant issued on January 12, 2016. (F2) Corrected option price. (F3) This stock option is fully vested. |